Martin E. Cearnal
Net Worth

Last updated:

What is Martin E. Cearnal net worth?

The estimated net worth of Mr. Martin E. Cearnal is at least $6,286,505 as of 20 Dec 2021. He owns shares worth $560,405 as insider and has received compensation worth at least $5,726,100 in Cumberland Pharmaceuticals Inc..

What is the salary of Martin E. Cearnal?

Mr. Martin E. Cearnal salary is $381,740 per year as Executive Vice President, Chief Commercial Officer & Director in Cumberland Pharmaceuticals Inc..

How old is Martin E. Cearnal?

Mr. Martin E. Cearnal is 80 years old, born in 1945.

What stocks does Martin E. Cearnal currently own?

As insider, Mr. Martin E. Cearnal owns shares in one company:

Company Title Shares Price per share Total value
Cumberland Pharmaceuticals Inc. (CPIX) Executive Vice President, Chief Commercial Officer & Director 178,473 $3.14 $560,405

What does Cumberland Pharmaceuticals Inc. do?

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

CPIX logo
CPIX
Cumberland Pharmaceuticals Inc.
$3.14

Martin E. Cearnal insider trading

Cumberland Pharmaceuticals Inc.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Stock 314 $4.33 $1,360
Purchase
Common Stock 240 $4.17 $1,001
Purchase
Common Stock 240 $4.53 $1,087
Purchase
Common Stock 200 $4.29 $858
Purchase
Common Stock 200 $4.28 $856
Purchase
Common Stock 200 $4.36 $872
Purchase
Common Stock 90 $4.82 $434
Purchase
Common Stock 90 $5.81 $523
Purchase
Common Stock 90 $6.15 $554
Purchase
Common Stock 90 $5.61 $505
Purchase
Common Stock 90 $4.46 $401
Purchase
Common Stock 90 $4.47 $402
Purchase
Common Stock 90 $3.84 $346
Purchase
Common Stock 90 $4.14 $373
Purchase
Common Stock 175 $4.61 $807
Purchase
Common Stock 175 $2.23 $390
Purchase
Common Stock 175 $2.26 $395
Purchase
Common Stock 175 $2.31 $404
Purchase
Common Stock 105 $2.29 $240
Purchase
Common Stock 105 $2.35 $247
Purchase
Common Stock 105 $3.31 $348
Purchase
Common Stock 105 $3.31 $348
Purchase
Common Stock 105 $3.31 $348
Purchase
Common Stock 105 $3.31 $348
Purchase
Common Stock 105 $3.31 $348
Purchase
Common Stock 105 $3.31 $348
Purchase
Common Stock 105 $3.31 $348
Purchase
Common Stock 105 $3.31 $348
Purchase
Common Stock 105 $3.31 $348
Purchase
Common Stock 105 $3.31 $348
Purchase
Common Stock 105 $3.31 $348
Purchase
Common Stock 105 $3.31 $348
Purchase
Common Stock 105 $3.31 $348
Purchase
Common Stock 105 $3.31 $348
Purchase
Common Stock 105 $3.31 $348
Purchase
Common Stock 105 $3.31 $348
Purchase
Common Stock 105 $3.31 $348
Purchase
Common Stock 105 $3.31 $348
Purchase
Common Stock 105 $3.31 $348
Purchase
Common Stock 105 $3.31 $348
Purchase
Common Stock 105 $3.31 $348
Purchase
Common Stock 105 $3.31 $348
Purchase
Common Stock 105 N/A N/A
Purchase
Common Stock 105 N/A N/A
Purchase
Common Stock 105 N/A N/A
Purchase
Common Stock 105 N/A N/A
Purchase
Common Stock 105 N/A N/A
Purchase
Common Stock 105 N/A N/A
Purchase
Common Stock 105 N/A N/A
Purchase
Common Stock 105 N/A N/A
Purchase
Common Stock 105 N/A N/A
Purchase
Common Stock 105 N/A N/A
Purchase
Common Stock 105 N/A N/A
Purchase
Common Stock 105 N/A N/A
Purchase
Common Stock 105 N/A N/A
Purchase
Common Stock 105 N/A N/A
Purchase
Common Stock 105 N/A N/A
Purchase
Common Stock 105 N/A N/A
Purchase
Common Stock 105 N/A N/A
Purchase
Common Stock 105 N/A N/A
Purchase
Common Stock 105 N/A N/A
Purchase
Common Stock 105 N/A N/A
Purchase
Common Stock 105 N/A N/A
Purchase
Common Stock 105 N/A N/A
Purchase
Common Stock 105 N/A N/A
Purchase
Common Stock 105 N/A N/A
Purchase
Common Stock 105 N/A N/A
Purchase
Common Stock 105 N/A N/A
Purchase
Common Stock 105 N/A N/A
Purchase
Common Stock 105 N/A N/A
Purchase
Common Stock 105 N/A N/A
Purchase
Common Stock 105 N/A N/A
Purchase
Common Stock 5,805 $2.84 $16,457
Purchase
Common Stock 5,805 $2.84 $16,457
Purchase
Common Stock 5,105 $3.03 $15,468
Purchase
Common Stock 5,105 $3.03 $15,468
Purchase
Common Stock 105 $2.84 $298
Purchase
Common Stock 105 $2.84 $298
Purchase
Common Stock 105 $2.84 $298
Purchase
Common Stock 105 $2.84 $298
Purchase
Common Stock 105 $2.84 $298
Purchase
Common Stock 105 $2.84 $298
Purchase
Common Stock 105 $2.84 $298
Purchase
Common Stock 105 $2.84 $298
Purchase
Common Stock 105 $2.84 $298
Purchase
Common Stock 105 $2.84 $298
Purchase
Common Stock 105 $2.84 $298
Purchase
Common Stock 80 $2.94 $235
Purchase
Common Stock 105 $2.84 $298
Purchase
Common Stock 105 $2.84 $298
Purchase
Common Stock 105 $2.84 $298
Purchase
Common Stock 105 $2.84 $298
Purchase
Common Stock 105 $2.84 $298
Purchase
Common Stock 105 $2.84 $298
Purchase
Common Stock 105 $2.84 $298
Purchase
Common Stock 105 $2.84 $298
Option
Options 3,700 $1.63 $6,013
Option
Common stock 7,400 $1.63 $12,025

Cumberland Pharmaceuticals key executives

Cumberland Pharmaceuticals Inc. executives and other stock owners filed with the SEC: